Journal Information Content Entity Continuant Continuant Entity Entity Periodical Generically Dependent Continuant Collection 2025-05-06T22:39:18 RDF description of Lancet Oncology - http://repository.healthpartners.com/individual/journal-Lancet-Oncology Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncology public Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation [editorial] Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials journal-Lancet-Oncology Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study